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ORIGINAL PAPER
Serelaxin in acute heart failure patients with and without atrial 
fibrillation: a secondary analysis of the RELAX-AHF trial
Gerasimos Filippatos1,13 · Dimitrios Farmakis1 · Marco Metra2 · Gad Cotter3 · Beth A. Davison3 · 
G. Michael Felker4 · Barry H. Greenberg5 · Tsushung A. Hua6 · Peter S. Pang7 · Piotr Ponikowski8 · Min Qian9 · 
Thomas A. Severin10 · Adriaan A. Voors11 · John R. Teerlink12 
Received: 15 July 2016 / Accepted: 27 December 2016 / Published online: 1 February 2017 
© Springer-Verlag Berlin Heidelberg 2017
Results AFib was present in 41.3% of patients. Sere-
laxin had a similar effect in patients with and without 
AFib, including dyspnea relief by visual analog scale 
through day 5 [mean change in area under the curve, 
541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 
(−63.30, 786.90), p = 0.0953 in non-AFib, interaction 
p = 0.5954] and all-cause death through day 180 [HR = 0.42 
(0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), 
p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin 
was similarly safe in the two groups and induced similar 
reductions in biomarkers of cardiac, renal and hepatic dam-
age. Stroke occurred more frequently in AFib patients (2.8 
vs. 0.8%, p = 0.0116) and there was a trend for lower stroke 
incidence in the serelaxin arm in AFib patients (odds ratios, 
0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, inter-
action p = 0.0518).
Conclusions Serelaxin was similarly safe and efficacious 
in improving short- and long-term outcomes and induc-
ing organ protection in acute HF patients with and without 
AFib.
Keywords Serelaxin · Relaxin · Acute heart failure · 
Atrial fibrillation
Introduction
Heart failure (HF) remains the most common reason for 
hospital admission in the elderly [1–4]. Although improve-
ments in re-admission rates have been recently observed, 
outcomes for patients admitted for HF remain poor, with 
high post-discharge mortality and rehospitalization rates 
[2–7].
Atrial fibrillation (AFib) is a common comorbid state 
in HF patients, including those admitted for acute HF [8]. 
Abstract 
Background Atrial fibrillation (AFib) is a common 
comorbidity in HF and affects patients’ outcome. We 
sought to assess the effects of serelaxin in patients with and 
without AFib.
Methods In a post hoc analysis of the RELAX-AHF trial, 
we compared the effects of serelaxin on efficacy end points, 
safety end points and biomarkers in 1161 patients with and 
without AFib on admission electrocardiogram.
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Table 1  Comparison of 
baseline characteristics between 
patients with and without atrial 
fibrillation (AFib) on admission
Baseline characteristic AFib, n = 479a No AFib, n = 680a p  valueb
Demographics
 Age (years) 74.6 (9.5) 70.2 (12.0) <0.0001
 Male 284 (59.3) 440 (64.7) 0.0608
 White/Caucasian 466 (97.3) 628 (92.4) 0.0003
 Geographic region <0.0001
  Eastern Europe 266 (55.5) 295 (43.4)
  Western Europe 89 (18.6) 115 (16.9)
  South America 26 (5.4) 45 (6.6)
  North America 23 (4.8) 90 (13.2)
  Israel 75 (15.7) 135 (19.9)
Heart failure characteristics
 Left ventricular EF 40.3 (14.5) 37.5 (14.5) 0.0015
 EF < 40% 217 (48.9) 380 (58.9) 0.0011
 Ischemic heart disease 226 (47.2) 376 (55.3) 0.0065
 Time from presentation to randomization (h) 7.6 (4.6) 8.1 (4.7) 0.0768
 CHF 1 month prior 362 (75.6) 497 (73.1) 0.3414
 NYHA class 30 days before admission 0.1274
  I 128 (26.8) 195 (29.0)
  II 115 (24.1) 187 (27.8)
  III 180 (37.7) 209 (31.1)
  IV 54 (11.3) 81 (12.1)
Clinical signs
 Body mass index, kg/m2 29.3 (5.3) 29.2 (6.0) 0.7501
 Syst. blood pressure, mmHg 141.5 (16.2) 142.6 (16.8) 0.2523
 Diast. blood pressure, mmHg 80.6 (13.8) 77.9 (14.5) 0.0018
 Heart rate, beat per minute 83.0 (15.9) 77.3 (13.8) <0.0001
 Respiratory rate, breaths per minute 21.9 (4.7) 21.9 (4.6) 0.8515
 HF hospitalization past year 161 (33.6) 235 (34.6) 0.7378
Congestion at baseline
 Edema 395 (83.0) 513 (75.9) 0.0037
 Orthopnea 459 (96.4) 645 (95.4) 0.3962
 Jugular vein distension 359 (76.7) 489 (74.5) 0.4054
 Dyspnea on exertion 469 (99.8) 665 (99.6) 0.6468
 Dyspnea by VAS 43.7 (20.5) 44.5 (19.6) 0.4915
 Rales 453 (95.2) 640 (94.5) 0.6336
Comorbidities
 Hypertension 417 (87.1) 587 (86.3) 0.7181
 Hyperlipidemia 223 (46.6) 392 (57.6) 0.0002
 Diabetes mellitus 196 (40.9) 353 (51.9) 0.0002
 Cigarette smoking 35 (7.3) 118 (17.4) <0.0001
 Stroke or other cerebrovascular event 66 (13.8) 91 (13.4) 0.8460
 Peripheral vascular disease 62 (12.9) 93 (13.7) 0.7181
 Asthma, bronchitis, or COPD 77 (16.1) 106 (15.6) 0.8229
 History of Atrial fibrillation or flutter 454 (94.8) 148 (21.8) <0.0001
 History of CRT or ICD procedures 112 (23.4) 182 (26.8) 0.1925
 Myocardial infarction 141 (50.5) 262 (60.0) 0.0132
 Depression 14 (2.9) 46 (6.8) 0.0036
Medication
 ACE inhibitor 244 (50.9) 388 (57.1) 0.0394
 ACEi or ARBs 314 (65.6) 472 (69.4) 0.1662
 Angiotensin-receptor blocker 83 (17.3) 101 (14.9) 0.2563
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Acute HF registries report a prevalence of AFib ranging 
between 27 and 45% [2]. There is a bidirectional pathoge-
netic relationship linking HF with AFib [9]. On one hand, 
HF leads to increased atrial pressures and neurohormo-
nal activation, resulting in structural and electrical atrial 
remodeling: factors that constitute the ideal substrate for 
the development of AFib [10, 11]. On the other hand, AFib 
doubles the risk for HF development. It is a frequent trig-
ger for HF decompensation resulting in a high overall risk 
of cardiovascular complications, including a fivefold higher 
risk of stroke [2, 12]. The presence of AFib directly affects 
the outcomes of HF patients, predicting a worse prognosis 
[13].
Serelaxin, a recombinant form of human relaxin-2, 
improves symptoms and outcomes in patients admitted 
for acute HF, as reported by the RELAX-AHF trial 
[14–18]. In this study, 53% of patients had a history of 
AFib, while 41% had AFib on screening electrocardio-
gram performed on admission [19, 20]. A previously 
published sub-group analysis showed no differential 
effects of seralaxin based on the presence or absence of 
a history of AFib or AFib at screening on key study end 
points [19]. In the present study, we sought to expand our 
knowledge on the efficacy and safety of serelaxin in acute 
HF patients with and without AFib at the time of presen-
tation by addressing all pre-specified efficacy and safety 
end points, adverse events and biomarkers of organ dam-
age. We further analyzed the clinical profile of patients 
with AFib as well as the independent prognostic signifi-
cance of AFib on patient outcomes.
Table 1  (continued) Baseline characteristic AFib, n = 479a No AFib, n = 680a p  valueb
 Beta-blocker 344 (71.8) 448 (65.9) 0.0325
 Aldosterone antagonist 166 (34.7) 199 (29.3) 0.0517
 Oral loop diuretic 30 days prior 42.3 (59.9) 46.4 (68.7) 0.2900
 Digoxin 152 (31.7) 76 (11.2) <0.0001
 Nitrates at randomization 31 (6.5) 50 (7.4) 0.5623
Devices
 Pacemaker 66 (13.8) 55 (8.1) 0.0018
 Implantable cardiac defibrillator 42 (8.8) 112 (16.5) 0.0001
 Biventricular pacing 33 (6.9) 80 (11.8) 0.0059
Baseline laboratory findings
 Hemoglobin, g/dL 12.83 (1.71) 12.77 (1.95) 0.5721
 White blood cell count, ×109/L 7.909 (2.723) 8.370 (2.916) 0.0082
 Lymphocyte, % 18.15 (7.27) 18.18 (8.19) 0.9433
 Glucose, mmol/L 7.29 (3.01) 8.07 (3.89) 0.0002
 BUN, mmol/L 9.80 (4.03) 9.75 (4.03) 0.8340
 Creatinine, umol/L 114.3 (31.5) 118.1 (34.2) 0.0621
 Cystatin C, mg/L 1.47 (1.43, 1.51) 1.44 (1.41, 1.47) 0.2294
 eGFR, mL/min per 1.73 m2 53.20 (12.98) 53.72 (13.06) 0.5097
 Sodium, mmol/L 141.0 (3.8) 140.7 (3.4) 0.3074
 Potassium, mmol/L 4.27 (0.63) 4.27 (0.64) 0.9697
 Calcium, mmol/L 2.26 (0.14) 2.27 (0.16) 0.5059
 Alanine aminotransferase, U/L (log transformed) 23.4 (22.2, 24.7) 23.7 (22.5, 24.9) 0.7569
 Albumin, g/L 40.41 (3.93) 40.11 (4.59) 0.2407
 Total cholesterol, mmol/L 3.94 (1.07) 4.20 (1.22) 0.0001
 CRP, mg/L (log transformed) 8.56 (7.57, 9.68) 8.49 (7.73, 9.31) 0.9101
 Uric acid, umol/L 478.4 (132.3) 473.8 (138.2) 0.5751
 NT-proBNP, ng/L (log transformed) 5279 (4919, 5665) 4905 (4553, 5284) 0.1599
 Troponin T, ug/L (log transformed) 0.031 (0.028, 0.033) 0.038 (0.036, 0.041) <0.0001
 GDF-15, ng/L (log transformed) 4598 (4329, 4883) 4167 (3953 4392) 0.0165
a Mean (SD), or geometric mean (95% CI) if log transformed, presented for continuous variables, and n 
(%) for categorical variables (% based on the total number of patients with a non-missing value of the end 
point)
b p value was based on t test (with Satterthwaite correction if unequal variances), Chi-square test, or Fish-
er’s exact test
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Methods
The design and primary results of the RELAX-AHF trial 
are described in detail elsewhere [21]. Briefly, the study 
randomized 1161 AHF patients to 48-h intravenous infu-
sion of serelaxin (30  μg/kg/day, n = 581) or placebo 
(n = 580) within 16  h from presentation. The study was 
approved by the institutional review boards and all subjects 
enrolled gave informed consent.
In the present analysis, we compared the effects of sere-
laxin versus placebo on pre-specified efficacy end points, 
safety end points, and biomarkers indicative of organ dam-
age, in patients with and without AFib. The presence of 
AFib was defined as evidence of either atrial fibrillation or 
atrial flutter on the screening electrocardiogram performed 
on admission.
The trial’s primary efficacy end points were dyspnea 
improvement, defined as the area under the curve of dysp-
nea change from baseline on a 100-mm visual analog scale 
(VAS-AUC) through day 5 and the presence of moderately 
or markedly better breathing compared to baseline reported 
on a 7-point Likert scale at 6, 12 and 24 h. Adverse events 
(AEs) were collected through day 5, serious AEs through 
day 14, rehospitalizations through day 60, and vital status 
through day 180. Rehospitalizations and deaths were adju-
dicated by an independent, blinded committee. The trial’s 
secondary efficacy end points included cardiovascular 
death or rehospitalization for heart or renal failure and days 
alive and out of hospital through day 60. Cardiovascular 
death through day 180 was pre-specified as an additional 
efficacy end point, and all-cause death through day 180 was 
a pre-specified safety end point. Stroke through day 180 
was defined to include any AE of stroke (through day 14), 
any rehospitalization for stroke (through day 60), or death 
due to stroke (through day 180). Biomarkers indicative of 
congestion and/or organ damage, including high-sensitivity 
troponin T (hs-TnT), N-terminal beta-type natriuretic pro-
peptide (NT-proBNP), cystatin C, creatinine, alanine ami-
notransferase (ALT), aspartate aminotransferase (AST) and 
growth differentiation factor-15 (GDF-15) were assessed 
serially using a central core laboratory.
Statistical analysis
Baseline characteristics were compared between patients 
with and without AFib, without imputation for missing val-
ues, using two-sample t test for continuous variables and 
Chi square or Fisher’s exact test for categorical variables. 
Estimates of the serelaxin treatment effect (odds ratios, 
mean differences, or hazard ratios) for patients with and 
without AFib and an interaction test were obtained from 
separate regression models (logistic regression, analysis of 
covariance, or Cox proportional hazards). For the analyses 
of outcomes in patients with and without AFib and the 
analyses of treatment effects, two subjects with unknown 
AFib status were imputed as without AFib. Missing base-
line covariates were also imputed as the mean for con-
tinuous variables or as the mode for categorical variables 
within the treatment group. Missing biomarker values were 
not imputed. Analyses were conducted on an intention-to-
treat basis. All p values were two sided, and values <0.05 
were considered to be statistically significant. Analyses 
were performed using SAS© release 9.2 (SAS Institute, 
Cary, NC, USA).
Results
Baseline characteristics in patients with and without 
AFib
From a total 1161 patients who underwent a screening 
electrocardiogram on admission, 479 patients had AFib 
(41.3%). In addition, 602 (51.9%) patients reported a his-
tory of AFib, although this was not used as a criterion for 
the present analysis. Patients with AFib were significantly 
older with a different race and geographic distribution than 
those without AFib (Table  1). Patients with AFib were 
less likely to have an ischemic etiology of HF or a reduced 
ejection fraction (HFrEF), but similar New York Heart 
Association (NYHA) class distribution when compared 
to patients without AFib. AFib patients had a higher rest-
ing heart rate than non-AFib patients, but similar systolic 
blood pressure. Symptoms and signs of congestion did not 
differ between the two groups with the exception of periph-
eral edema, which was more frequent in patients with AFib. 
Several comorbid conditions including hyperlipidemia, dia-
betes mellitus, smoking, history of myocardial infarction 
and depression were less frequent in patients with AFib. A 
history of hypertension, lung disease and cerebrovascular 
or peripheral arterial disease did not differ between the two 
groups. Regarding cardiovascular therapies, patients with 
AFib were more frequently prescribed beta-blockers and 
digoxin, and had more frequently undergone a pacemaker 
implantation. However, they were less likely to have a car-
diac defibrillator or a biventricular pacing system. With 
respect to baseline laboratory findings, renal, liver func-
tion and natriuretic peptides did not differ between the two 
groups. Patients with AFib, however, had lower troponin T 
and higher GDF-15 levels.
Efficacy and safety of serelaxin in patients 
with and without atrial fibrillation
Atrial fibrillation was present in 233 of 580 (40.2%) 
patients in the serelaxin arm and in 246 of 579 (42.5%) 
448 Clin Res Cardiol (2017) 106:444–456
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patients in the placebo arm (p = 0.424). Most of the study 
end points did not differ significantly between patients with 
and without AFib after multivariable adjustment, but AFib 
patients had a significantly higher incidence of cardiovas-
cular mortality at 180 days (adjusted p = 0.0173, Table 2).
The effect of serelaxin versus placebo on several study 
end points in patients with and without AFib is outlined 
in Table 3. There was no differential effect of serelaxin on 
dyspnea relief according to VAS scale up to day 5 (interac-
tion p = 0.5954; Table 3; Fig. 1) or by Likert scale at 6, 12 
and 24  h (Table  3) Serelaxin induced a similar reduction 
in the incidence of worsening HF (interaction p = 0.7423) 
irrespective of the presence or absence of AFib. Simi-
larly, the length of hospital stay did not differ (interaction 
p = 0.3837). Cardiovascular death or hospitalization for 
HF or renal failure through day 60 and all-cause death and 
cardiovascular mortality at 180 days were neither signifi-
cantly affected by serelaxin in either of the two group inter-
action (interaction p = 0.1583, 0.0643 and 0.1472, respec-
tively; Fig. 2).
Stroke through 180 days occurred in 13 patients 
with AFib (2.8%) and 5 patients without AFib (0.8%, 
p = 0.0116). There was a trend for a lower incidence of 
stroke in the serelaxin arm in patients with AFib [hazard 
ratio serelaxin versus placebo, 0.31 (0.09, 1.13) in AFib 
versus 3.88 (0.43, 34.71) in patients without AFib, interac-
tion p = 0.0518].
The effect of serelaxin versus placebo on AEs in patients 
with and without AFib is shown in Table  4. The overall 
incidence of serious AEs did not differ based on the pres-
ence or absence of AFib (interaction p = 0.3905). The same 
applied to the incidence of AEs indicative of hypotension 
Table 2  Outcomes in patients with and without atrial fibrillation
a Mean (95% CI), n (K-M %) and n (%) are presented for continuous outcome, survival outcome and binary outcome, respectively
b Two subjects with unknown AFib status were imputed as without AFib (treatment-specific mode)
c Treatment effect represents mean difference (from linear regression analysis), hazard ratio (from Cox proportional hazards model) and odds 
ratio (from logistic regression analysis) for continuous outcome, survival outcome and binary outcome, respectively
d Dyspnea VAS AUC to day 5 is adjusted for age, US-like, weight, dyspnea on exertion, hypertension, mitral regurgitation, history of atrial 
fibrillation or flutter, alkaline phosphatase, sodium, body temperature (linear spline at Q1), log2 troponin (linear spline at Q2), dyspnea by VAS 
(cubic), uric acid (cubic); WHF is adjusted for white race, height (linear spline at 173), diastolic BP(linear spline at 70), heart rate (trichoto-
mized: <73, [73, 85), ≥85), respiratory rate, dyspnea by VAS, mm (cubic), coronary artery bypass graft, hyperthyroidism, total bilirubin, total 
cholesterol, albumin, troponin (log2 transformed, linear spline at −4.2); CV death or HF/RF rehospitalization through day 60 is adjusted for 
white race, NYHA class 30 days before systolic BP, respiratory rate, number of HF hospitalizations past year, orthopnea (ordinal), asthma or 
bronchitis or COPD, hyperthyroidism, lymphocytes %, BUN, phosphate (cubic), sodium, total protein (linear spline at 68); CV mortality through 
day 180 is adjusted for the following variables: US-like, systolic BP, orthopnea (ordinal), angina, hyperthyroidism, mitral regurgitation, atrial 
fibrillation/flutter at screening, white blood cell count, lymphocytes %, BUN, sodium, potassium, calcium, total protein, log2 troponin, log2 NT-
proBNP. All-cause death to day 180 is adjusted for age, CHF 1 month previously, stroke or other cerebrovascular events, respiratory rate, systolic 
BP, edema (2/3 versus 0/1), orthopnea (2/3 versus 0/1), lymphocytes (%), sodium, creatinine and log2 troponin
Clinical end points AFib, n = 479
Estimatea
No AFib, n = 682
Estimatea,b
Unadjusted effect of AFib (yes 
versus no)
Adjusted effect of AFib (yes 
versus no)
(95% CI) p  valuec (95% CI) p  valuec,d
Dyspnea improvement 
by VAS to day 5, 
mm-h
2222.58 (1962.77, 
2482.39)
2749.22 (2538.24, 
2960.20)
−526.64 (−858.50, 
−194.78)
0.0019 −166.06 (−570.24, 
238.11)
0.4207
Dyspnea improvement 
by Likert scale at 6, 
12 and 24 h
110/479 (23.0%) 196/682 (28.7%) 0.74 (0.56, 0.97) 0.0282 – –
Worsening heart fail-
ure (WHF)
53/479 (11.1%) 57/682 (8.4%) 1.34 (0.92, 1.96) 0.1258 1.13 (0.67, 1.91) 0.6446
Hospitalization length, 
days
11.82 (10.80, 12.84) 8.82 (8.26, 9.37) 3.00 (1.92, 4.08) <0.0001 – –
Cardiovascular death 
or HF/RF hospi-
talization through 
day 60
69/479 (14.5%) 82/682 (12.1%) 1.21 (0.88, 1.67) 0.2414 1.13 (0.81, 1.59) 0.4739
All-cause death 
through day 180
51/479 (10.7%) 56/682 (8.3%) 1.33 (0.91, 1.95) 0.1372 1.46 (0.98, 2.18) 0.0651
Cardiovascular mortal-
ity to day 180
43/479 (9.1%) 45/682 (6.7%) 1.40 (0.92, 2.12) 0.1170 1.71 (1.10, 2.67) 0.0173
Stroke through day 180 13/479 (2.8%) 5/682 (0.8%) 3.77 (1.34, 10.58) 0.0116 – –
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or renal or hepatic impairment. It should be noted that there 
was no difference in anticoagulation use at baseline and 
from baseline through day 14 and day 60 among the study 
groups. In addition,  CHA2DS2-VASc score was similar 
among the study groups (Table 5).
Effects of serelaxin on biomarkers of organ damage 
in patients with and without atrial fibrillation
The effects of serelaxin versus placebo on biomarkers of 
organ damage were similar irrespective of AFib presence 
at baseline (Table  6; all interaction p levels were nonsig-
nificant). There was a less pronounced increase in cystatin 
C with serelaxin than with placebo treatment in both AFib 
groups, while creatinine decreased in the serelaxin group 
and increased in the placebo group. There were greater 
reductions in NT-proBNP, AST, ALT, and GDF-15 at 48 h 
in the serelaxin group than in the placebo group, both in 
patients with and without AFib. Serelaxin induced simi-
lar reductions in relative changes in troponin T; however, 
in patients with AFib troponin T increased in the placebo 
group and remained the same in the serelaxin group, while 
in patients without AFib troponin T stayed the same in pla-
cebo patients and decreased in serelaxin patients.
Atrial fibrillation during follow-up
Atrial fibrillation or flutter was reported in 13 patients by 
day 14; the incidence was similar in the serelaxin (n = 7) 
and placebo (n = 6) groups. Ten patients, seven in the sere-
laxin group and three in the placebo group, were rehospi-
talized for AFib through day 60. In patients without AFib 
Table 3  Treatment effect (serelaxin versus placebo) on various outcomes in patients with and without atrial fibrillation (AFib)
a Mean (95% CI) presented for continuous outcome, n (K-M %) for survival outcomes, n (%) for binary outcomes
b Treatment effect represents the mean difference estimated from linear regression models for continuous outcomes, the hazard ratio from Cox 
regression for time-to-event outcomes, and the odds ratio from logistic regression for binary outcomes
c Two subjects with unknown AFib status were imputed as without AFib (treatment-specific mode)
d Interaction p value is based on test of treatment by AF interaction from linear regression, Cox or logistic regression model as appropriate
e Result presented in [19]
Outcome AFib, n = 479 No AFib, n = 682c Inter-
action 
p 
 valued
Serelaxin, 
n = 233a
Placebo, n = 246a Treatment effect 
(95% CI)
p  valueb
Serelaxin, 
n = 348a
Placebo, n = 334a Treatment, effect 
(95% CI)
p  valueb
Dyspnea 
improvement by 
VAS-AUC to 
day 5, mm-he
2500.48 
(2165.85, 
2835.11)
1959.37 
(1565.60, 
2353.13)
541.11 (33.79, 
1048.44)
0.0366
2926.41 
(2654.92, 
3197.90)
2564.61 
(2239.43, 
2889.79)
361.80 (−63.30, 
786.90)
0.0953
0.5954
Dyspnea 
improvement by 
Likert scale at 
6, 12 and 24 h
55 (23.6%) 55 (22.4%) 1.07 (0.70, 1.64)
0.7457
101 (29.0%) 95 (28.4%) 1.03 (0.74, 1.43)
0.8671
0.8784
Worsening heart 
failure
19 (8.2%) 34 (13.8%) 0.57 (0.32, 1.00)
0.0506
20 (5.8%) 37 (11.1%) 0.50 (0.29, 0.86)
0.0126
0.7423
Hospitalization 
length, days
11.12 (9.77, 12.48) 12.48 (10.96, 
13.99)
−1.35 (−3.00, 
0.30)
0.1085
8.62 (7.79, 9.45) 9.02 (8.28, 9.76) −0.39 (−1.78, 
0.99)
0.5761
0.3837
Cardiovascular 
death or HF/RF 
hospitalization 
through day  60e
30 (13.0%) 39 (16.0%) 0.80 (0.49, 1.28)
0.3486
46 (13.4%) 36 (10.9%) 1.27 (0.82, 1.96)
0.2866
0.1583
All-cause death 
through day 
180
15 (6.5%) 36 (14.8%) 0.42 (0.23, 0.77)
0.0051
27 (7.9%) 29 (8.7%) 0.90 (0.53, 1.52)
0.6888
0.0643
Cardiovascu-
lar mortality 
through day 
 180e
13 (5.6%) 30 (12.4%) 0.44 (0.23, 0.85)
0.0139
21 (6.1%) 24 (7.3%) 0.84 (0.47, 1.52)
0.5713
0.1472
Stroke through 
day 180
3 (1.30%) 10 (4.23%) 0.31 (0.09, 1.13)
0.0759
4 (1.16%) 1 (0.32%) 3.88 (0.43, 
34.71)
0.2255
0.0518
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at baseline screening, there were eight episodes of AFib or 
flutter through day 14, including five (1.44%) in the sere-
laxin group and three (0.90%) in the placebo group [OR, 
1.61, 95% CI (0.31, 10.4), p = 0.725].
Discussion
A 48-h serelaxin infusion in patients with acute HF 
improved dyspnea and congestion, reduced early HF wors-
ening and hospital stay and improved long-term outcome 
in terms of cardiovascular and all-cause mortality at 6 
months [14]. The effects of serelaxin versus placebo on 
dyspnea relief to day 5, cardiovascular death or rehospitali-
zations for heart or renal failure at 60 days or all-cause or 
cardiovascular mortality at 180 days were further shown 
to be generally consistent across several patient subgroups, 
including a history of AFib and AFIb on admission [17]. In 
the present analysis, we expanded those results by address-
ing the interaction between treatment assignment (sere-
laxin or placebo) and the presence or absence of AFib on 
admission on all efficacy and safety end points, including 
dyspnea improvement at 6, 12 and 24  h, worsening HF, 
hospitalization length, all-cause and cardiovascular death at 
180 days and incidence of stroke over the same time period.
Patients with AFib on admission enrolled in the 
RELAX-AHF trial differed in HF etiology and phenotype 
as well as in baseline comorbidities compared to patients 
without AFib. In addition, AFIb patients had a higher 
adjusted incidence of cardiovascular mortality at 180 days. 
However, dyspnea response to therapy, HF worsening and 
cardiovascular death or hospitalization for HF or renal fail-
ure through day 60 as well as all-cause death through day 
180 were similar in the two subgroups after multivariable 
adjustment. This finding suggests that worse outcomes 
observed in acute HF patients with AFib may be partly 
influenced by the different profile of those patients rather 
than being wholly attributable to the arrhythmia per se.
Serelaxin was similarly safe in the two groups in terms 
of serious adverse events or events indicative of hypoten-
sion, or renal or hepatic impairment. Not only was sere-
laxin safe, but it also seemed to provide organ protection, 
as the previously documented beneficial effect of serelaxin 
on biomarkers of organ damage was consistent in patients 
with and without AFib. In addition, although the incidence 
of stroke was, as expected, higher in patients with AFib, 
Fig. 1  Patient-reported dyspnea change (serelaxin versus placebo) in patients with and without atrial fibrillation (AF), according to visual 
analog scale from baseline to day 5
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interestingly serelaxin tended to reduce its incidence in 
those particular patients.
Atrial fibrillation is known to confer a fivefold increase 
in the risk of stroke [12]. Studies have shown that even 
subclinical AFib episodes as short as 6 min or periopera-
tive AFib in patients undergoing non-cardiac surgery are 
followed by an increased long-term risk of stroke [22–25]. 
Stroke may be a devastating condition associated with 
Fig. 2  Kaplan–Meier curves (serelaxin versus placebo) for cardiovascular death through day 180 (upper panel) and all-cause death through day 
180 (lower panel) in patients with and without atrial fibrillation (AF)
452 Clin Res Cardiol (2017) 106:444–456
1 3
significant morbidity and mortality. The present post hoc 
analysis, despite the rather short follow-up period, con-
firmed a higher risk of stroke in AFib patients. Interest-
ingly, serelaxin was followed by a lower incidence of 
stroke in those patients compared to placebo. Relaxin is a 
known vasoactive peptide that modifies beneficially arte-
rial resistance and compliance. Regarding the cerebral 
vasculature, in particular, relaxin seems to have specific 
beneficial effects that have led to the hypothesis that it 
may play a protective role against ischemic stroke [26]. 
Experimental studies have shown that relaxin pretreatment 
reduced infarct size after middle cerebral artery occlusions 
in rats, an action accomplished through the activation of 
the relaxin family peptide receptor 3 (RXFP3), a process 
that also involved activation of the endothelial nitric oxide 
synthase (eNOS) pathway [27–29]. Those effects within 
the cerebral vascular bed may lead to vasodilation and 
improved brain tissue perfusion. In a small clinical study in 
36 patients recovering from stroke, relaxin plus rehabilita-
tion induced a greater recovery compared to rehabilitation 
alone at 20 and 40 days as indicated by measures of physi-
cal activity, cognitive function and global function [26]. It 
should be stressed however that the incidence rate of stroke 
was low and therefore those results should be interpreted 
with caution.
Besides its vasodilatatory and anti-ischemic actions dis-
cussed earlier, relaxin seems to possess anti-inflamatory 
and antifibrotic properties [30]. As inflammation and fibro-
sis are thought to be important aspects in the pathophysiol-
ogy of AFib, it has been postulated that relaxin may have a 
role in the management of AFib [31]. In an experimental 
study in hypertensive rats, relaxin suppressed AFib trig-
gered by programmed stimulation [32]. The suppression of 
AFib was achieved by increasing conduction velocity from 
a combination of reversal of atrial fibrosis and hypertrophy 
and by increasing  Na+ current density [32]. In RELAX-
AHF, the occurrence of AFib during follow-up was not 
systematically recorded; there were only a few spontane-
ous reports of AFib as an adverse event. As a result, the 
effects of the drug on the occurrence of AFib could not be 
assessed, but this may be the aim of a future study.
The results of the present study should be cautiously 
treated as they are derived by a post hoc subgroup analysis 
of a randomized trial. In addition, the main RELAX-AHF 
study was not primarily designed and powered to assess 
medium and long-term prognostic outcomes and therefore 
the corresponding findings should be carefully interpreted.
In conclusion, serelaxin was overall similarly safe and 
efficacious in improving short- and long-term clinical out-
comes and inducing organ protection in acute HF patients 
Table 4  Treatment effect (serelaxin versus placebo) on adverse events (AE) in patients with and without atrial fibrillation (AFib)
AE adverse events
a Blood pressure decreased, dizziness, loss of consciousness, hypotension, orthostatic hypotension, presyncope, somnolence or syncope
b Azotemia, blood creatinine increase, oliguria, proteinuria, renal failure, acute renal failure or renal impairment
c Blood bilirubin increase, cholestasis, hepatic congestion, hepatic cyst, hepatic steatosis, hyperbilirubinemia, hypoalbuminemia, INR increase or 
liver disorder
Adverse event AFib, n = 479 No AFib, n = 680 Interaction p 
valueSerelaxin, 
n = 233
Placebo, n = 246 Oddsratio(95% 
CI)
p value
Serelaxin, 
n = 347
Placebo, n = 333 Odds ratio (95% 
CI)
p value
Patients with 
any serious AE 
through day 14
26 (11.16%) 45 (18.29%) 0.56 (0.32, 0.97)
0.0293
43 (12.39%) 51 (15.32%) 0.78 (0.49, 1.24)
0.3172
0.3905
Patients with AE 
indicative of 
hypotension 
through day 
 14a
10 (4.29%) 9 (3.66%) 1.18 (0.42, 3.35)
0.8166
18 (5.19%) 18 (5.41%) 0.96 (0.46, 1.99)
1.0000
0.7769
Patients with AE 
indicative of 
renal impair-
ment through 
day  14b
4 (1.72%) 12 (4.88%) 0.34 (0.08, 1.15)
0.0737
13 (3.75%) 20 (6.01%) 0.61 (0.27, 1.31)
0.2116
0.5189
Patients with AE 
indicative of 
hepatic impair-
ment through 
day  14c
1 (0.43%) 7 (2.85%) 0.15 (0.00, 1.16)
0.0688
2 (0.58%) 4 (1.20%) 0.48 (0.04, 3.36)
0.4422
0.5491
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with and without AFib. However, prospective trials are 
required to confirm those findings.
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